Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

with twice-weekly dosing by intravenous infusion after a titration period of two once-weekly doses, based on the patient's body weight. Sanofi estimates that the annual cost for a typical patient ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.

Previous bird flu outbreaks and decades-old public health infrastructure have led industry to protect the hens used for ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

The approval is for both a 3 milliliter single-patient-use prefilled pen and a 10 milliliter multiple-dose vial ... FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...